Steven R Sarkisian, Robert E Ang, Andy M Lee, John P Berdahl, Sebastian B Heersink, James H Burden, Long V Doan, Kerry G Stephens, David Applegate, Angela C Kothe, Dale W Usner, L Jay Katz, Tomas Navratil
INTRODUCTION: This prospective, multicenter, randomized, double-masked pivotal phase 3 trial evaluated the efficacy and safety of the travoprost intracameral SE-implant (slow-eluting implant, the intended commercial product) and FE-implant (fast-eluting implant, included primarily for masking purposes) compared to twice-daily (BID) timolol ophthalmic solution, 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). METHODS: The trial enrolled adult patients with OAG or OHT with an unmedicated mean diurnal intraocular pressure (IOP) of ≥ 21 and unmedicated IOP ≤ 36 mmHg at each diurnal timepoint (8 A...
February 12, 2024: Ophthalmology and Therapy